Introduction
The growth of prostate cancer cells is regulated by several factors, including steroid hormones, growth factors and cytokines [1] . For patients with locally advanced and/or metastatic prostate cancer, hormone manipulation through androgen blockade is the main treatment modality [2] . However, the treatment response is often transient and a majority of patients become resistant to ablation treatment within 2-3 years. Once failure occurs, few therapeutic options remain. In therapyresistant tumors, however, androgen receptors (ARs) may remain active, possibly because of cross talk between AR and multiple cell membrane receptor-initiated pathways. These activated intracellular signaling cascades include mitogen-activated protein kinase/extracellular signalregulated kinase (MAPK/ERK), phosphatidylinositol-3 kinase/AKT (PI3K/AKT) [3] and signal transducer and activator of transcription 3 (STAT3) [4] . Additionally, protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs) play a crucial role in the regulation of these pathways. In fact, if the balance between PTPs and PTKs is disrupted and tyrosine-phosphorylated proteins accumulate, abnormal proliferation and cell function may result [5] .
We have recently shown that the down-regulation of SHP-1 in prostate cancer cells is associated with high rates of cell proliferation, increased risk of biochemical recurrence and clinical progression following radical prostatectomy [6] . SHP-2, a Src homology 2 (SH2) domain-containing PTP sharing homology with SHP-1 [7] , is expressed widely in a variety of cells and tissues [7] . SHPs are intimately involved in many cellular activities, including cytoskeleton maintenance, cell division and differentiation [8] . SHP-2 is believed to upregulate a variety of signal transduction processes. In a number of studies, SHP-2 has also been shown to promote cell survival [8] . Indeed, SHP-2 promotes the activation of the Ras-MAPK signaling pathway through receptors for various growth factors and cytokines [9] . However, other investigations have demonstrated that SHP-2 inhibits PDGF signaling [10] and accelerates the induction of apoptosis [11] through STAT5 dephosphorylation [12] .
Material and methods
Cell cultures LNCaP cells derived from metastatic prostate cancer of the lymph nodes, DU145 cells derived from metastatic prostate cancer of the brain, and PC3 cells derived from metastatic prostate cancer of the bone were obtained from American Type Culture Collection (Manassas, VA). LNCaP cells were maintained in RPMI 1640 medium (Invitrogen, San Diego, CA) containing 10 % fetal calf serum (FCS; Invitrogen). DU145 and PC3 were maintained in a humidified atmosphere of 5 % CO 2 at 37°C in DMEM medium (Invitrogen) containing 10 % FCS. The LNCaP-IL6+ sub cell line was provided by Zoran Culig [13] and was grown in the manner described above for LNCaP cells (but supplemented with 5 ng/mL of IL6).
Prostate cancer tissue microarray analysis and cell line arrays The prostate cancer tissue microarray included tumor specimens obtained from 122 patients treated between 1998 and 2003 at Skåne University Hospital, Malmö, Sweden, by open radical prostatectomy for localized prostate cancer. The patients provided informed consent, and the study was approved by the Regional Ethical Review Board at Lund University, Sweden (approval number DN. 445-07). Patient and tumor characteristics are detailed in (Table 1) . After a mean followup period of 58.8 months, two patients had died from prostate cancer, two patients had died from other causes, and 118 patients remained alive.
Tissue microarrays were constructed as previously described [14] . In brief, areas representing cancer and normal prostate tissue were marked on hematoxylin/eosin-stained sections. Two 1.00-mm tissue cores were then extracted and mounted using a manual array device (MTA-1 Beecher Instruments Inc., Sun Prairie, WI). Immunohistochemical (IHC) staining for SHP-2 was performed using an automated IHC staining procedure (Techmate 500 Dako, Copenhagen, Denmark) and a polyclonal anti-human SHP-2 antibody (C-18) (Santa Cruz Biotechnology, Santa Cruz, CA). Briefly, 4-μm-thick sections were dried, deparaffinized, rehydrated, and incubated with Target Retrieval Solution (pH9.9; Dako) in a microwave oven for 2 min each at 900, 750, 650, and 300 W. The sections were incubated at a primary antibody concentration of 0.2 μg/ ml. Dako REAL EnVision Detection System Peroxidase/ DAB (Dako) was used for secondary antibody incubation and visualization. Hematoxylin was used to counter-stain cell nuclei. Evaluation of the stained sections was completed by three of the authors (HT, LB, and PH). We were able to evaluate SHP-2 expression in 105 cases. The remaining samples were lost or damaged during sectioning or staining. Cytoplasmic staining intensity was graded from 0 to 3: 0 corresponding to "no staining," 1 to "weak staining," 2 to "moderate staining," and 3 to "strong staining." Nuclear staining was graded as either positive or negative. The percentage of stained cells was categorized as 0, 30, 50, 70 or 100 %. For survival analysis, SHP-2 staining intensity was classified into high (scores of 2 and 3) and low (scores of 0 and 1). Similarly, the percentage of stained cells was classified into ≤50 and >50 %. LNCaP, LNCaP-IL6+, DU145, and PC3 cell lines were pelleted and fixed in 4 % paraformaldehyde, embedded in paraffin and IHC stained as described above.
SHP-2 tyrosine phosphatase activity assay In order to measure the activity of SHP-2 in the cytoplasm and nucleus, subcellular fractionation of LNCaP, LNCaP-IL6+, DU145, and PC3 was performed using lysis buffer; 10 Mm HEPES pH7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 1 % Triton X-100, 15 % Complete protease inhibitor, 1 mM PMSF for cytoplasmic extraction, and RIPA buffer for nuclei extraction. To confirm the fractionation, 30 μg of protein was subjected to a 10 % SDS-PAGE and transferred to a PVDF membrane. The membrane were blocked in Odyssey's blocking buffer (Li-Cor Biotechnology, NE) and probed with polyclonal goat anti-Lamin B diluted 1:1,000 (Santa Cruz Biotechnology, Santa Cruz, CA). Thousand micrograms of fractionated lysates from cytoplasm and nuclei, respectively, were then incubated with a rabbit anti-human SHP-2 antibody for 2 h at 4°C and immunoprecipitated with protein G-beads (Amersham Biosciences, Amersham, UK) for 1 h at 4°C. A PTP-activity assay was then performed, where 20 μl of bead solution was incubated with 20 μl of buffer (100 mM Bis-Tris pH6.0, 150 mM NaCl, and DTT 5 mM) and 60 μl of pNPP-solution for 45 min at 37°C. To determine the background activity, one sample was immunoprecipitated with rabbit antihuman IgG-antibody (Dako, Copenhagen, Denmark). After 45 min, the optical density (OD) was measured at 405 nm. The OD correlates with the amount of free phosphate-groups that is representative of the SHP-2-specific PTP activity in the analyzed cells.
Statistical analysis Spearman's correlation was used to correlate SHP-2 expression with clinical parameters. A Cox's proportional hazard regression model was used for univariate and multivariable analyses. Low staining intensity and the percentage of positive cells were used for the reference categories, and negative nuclear staining was used for calculating the hazard ratios. Biochemical recurrence (BCR) was defined as two PSA tests >0.2 ng/ml. Clinical progression included BCR, death from prostate cancer or adjuvant radiation therapy. All statistical analyses were performed using SPSS version 16.0 (SPSS Inc.). Diagrams representing phosphatase activity are presented as mean±SEM. Data in the diagrams were analyzed using Student's t test. All statistical tests were two-sided. p values <0.05 were considered significant.
Results
Analysis of SHP-2 protein expression and function in LNCaP, LNCaP-IL6+, DU145, and PC3 cells SHP-2 immunoreactivity was detected in the cytoplasm and nuclei in all four cell lines; however, DU145 and LNCaP-IL-6+ showed higher expression of SHP-2 and more cells that expressed SHP-2 in the nuclei (Fig. 1a) . Tyrosine phosphatase analysis revealed that the SHP-2 activity was overall higher in the LNCaP-IL6+ cell line compared with the LNCaP, DU145 and PC3 cell lines. All four cell lines showed high SHP-2 activity in the nucleus, which was similar to or higher (LNCaP-IL6+, p<0.03) than that in the cytoplasm. (Fig. 1b) . SHP-2 expression in prostate cancer tissue SHP-2 expression was observed in epithelial and cancer cells as described below. In some cases, staining of stromal cells was also observed. SHP-2 expression was evaluated in 105 samples. The remaining cases were not analyzed because of the core loss during sectioning or staining. Representative photomicrographs are shown in Fig. 2 . Three cores showed no cytoplasmic staining, 15 cores showed weak staining, 58 showed moderate staining, and 29 showed strong staining. In 68 cores, nuclear staining was absent, and in 37 cores, the nuclei were positively stained.
Correlation of SHP-2 with clinicopathological parameters and survival analysis We used statistical analyses to assess the potential association of the intensity of cytoplasmic SHP-2 expression, the percentage of stained cells and nuclear staining with tumor characteristics (Table 1) . SHP-2 staining did not correlate with preoperative serum PSA levels, Gleason grades or other tumor characteristics. The intensity of SHP-2 immunostaining was classified into low (scores 0 and 1) versus high (scores 2 and 3) groups. The percentage of positive cells was divided into ≤50 % versus >50 % groups. Using a Spearman's analysis, we found that both the SHP-2 intensity and the percentage of positive cells were inversely correlated with prostate volume (p00.04 and p00.042 respectively) whereas nuclear SHP-2 staining was positively correlated with extracapsular extension (p00.039). b Phosphatase activity of SHP-2 in cytoplasmic and nuclear fractions analyzed with pNPP phosphatase assay. Lamin B was used as a control of the fractionation Fig. 2 Representative photomicrographs of SHP-2 immunohistochemistry in prostate cancer cores. SHP-2 expression was scored on the basis of staining intensity from 0 to 3. Zero corresponds to "no staining," 1 to "weak staining," 2 to "moderate staining," and 3 to "strong staining." Nuclear staining was scored qualitatively as either positive or negative (insets in 2 and 3)
Survival analysis BCR, defined as two post-operative serum PSA analyses >0.2 ng/ml, is commonly used to monitor outcomes following radical prostatectomy. We investigated whether the SHP-2 intensity, percentage of positive cells, and presence of nuclear staining was correlated with clinical outcomes, using BCR-free time and clinical progression-free time as our primary endpoints. Twenty-three of the 105 (22 %) patients experienced BCR during the follow-up period. (Table 2) .
Discussion
Recently, we demonstrated that decreased SHP-1 expression in prostate cancer cell lines was associated with high proliferation rates. Moreover, in biopsy cores obtained clinically, decreased SHP-1 expression was associated with an increased risk of recurrence and clinical progression following radical prostatectomy [6] . Here, we show that decreased SHP-2 expression or a lack of such expression is correlated with clinical progression and shorter time to BCR. Furthermore, the multivariable analysis showed that SHP-2 was an independent predictor of BCR after controlling for preoperative PSA level, Gleason score, extra capsular extension, seminal vesicle invasion, and positive surgical margins. In addition, low SHP-2 staining intensity and low SHP-2-positive cell staining percentage of SHP-2-positive cells correlated with increased prostate volume. The catalytic activity of SHP-2 is required for the modulation of ERK/MAPK and PI3K/AKT pathways downstream of receptor tyrosine kinases [7] . Moreover, SHP-2 is required for the full activation of Ras since it is thought to regulate an upstream element necessary for Ras activation [9] . In MCF10A non-malignant mammary cells, Gab2 overexpression increases the proliferative potential in a SHP-2-dependent manner [15] . However, SHP-2 has also been reported to promote cell death and induce apoptosis [10] [11] [12] .
In this study, we analyzed the expression and activity of SHP-2 in the prostate cancer cell lines LNCaP, LNCaP-IL6 +, DU145, and PC3. In all cell lines, SHP-2 was detected in both cytoplasm and nuclei. Similarly, SHP-2 activity was also demonstrated in both cytoplasm and nuclei. The level of nuclear SHP-2 activity in LNCaP-IL6+ was higher than in other prostate cancer cell lines. The function of nuclear SHP-2 in prostate cancer could be involved in migration and invasion since nuclear expression correlated with extracapsular extension of the cancer. Prior studies have also reported SHP-2 in the nucleus [16] [17] [18] [19] . Since SHP-2 lacks a typical nuclear localization signal sequence, it could be transported to the nucleus in association with proteins such as Gab1 [19] . Although it remains unclear, differential compartmentalization may alter SHP-2 function. For example, SHP-2 has been associated with the regulation of STAT5a as well as telomerase reverse transcriptase in the nucleus [17, 19] . However, further studies are required to determine whether this PTP functions similarly in prostate cancer.
